[EATG Global HIV News daily digest] Digest #32-2010

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -






  




Latest Headlines




  Shorter treatment may be adequate for genotype 1 hepatitis C if started during acute infection
  Hepatitis Saturday 20 February 2010
					
  
HIV positive gay/bisexual men with acute hepatitis C virus (HCV)
coinfection responded as well to 24 weeks of interferon-based therapy
as they did to 48 weeks, even though most had hard-to-treat HCV
genotypes 1 or 4.
  SOURCE:
HIVandHepatitis.com




  Does liver fibrosis progress faster in people who have HIV when they acquire hepatitis C?
  Hepatitis Saturday 20 February 2010
					
  
HIV positive men who subsequently became infected with hepatitis C
virus appeared to have a suspiciously rapid rate of liver disease
progression in the European NEAT study. 
  SOURCE:
HIVandHepatitis.com




  HBV DNA not detected in semen of men with chronic hepatitis B successfully treated with nucleotide analogs
  Hepatitis Saturday 20 February 2010
					
  
HIV positive and negative men with chronic hepatitis B who achieved
undetectable serum HBV DNA during treatment with nucleotide analogs
such as tenofovir also cleared HBV genetic material in their semen,
suggesting a reduced risk of sexual transmission.
  SOURCE:
HIVandHepatitis.com




  Malaria parasite mechanism identified
  Tuberculosis & Malaria Saturday 20 February 2010
					
  
Malaria remains one of the most deadly infectious diseases. Yet, how
Plasmodium, the malaria parasite, regulates its infectious cycle has
remained an enigma despite decades of rigorous research.
  SOURCE:
Machines Like Us




  Gene therapy shows promise against HIV
  Basic Science Saturday 20 February 2010
					
  
Early findings suggest it could work, but application remains years away.
  SOURCE:
US News & World Report




  Prioritise and protect access to medicines in Central America
  Access to treatment Saturday 20 February 2010
					
  
Press release from Health Action International (HAI) Europe on behalf
of the Latin America- European Alliance on Access to Medicines.
  SOURCE:
HAI




  Injecting drug users reap the same benefits of HIV antiretroviral therapy than nonusers: presented at CROI
  Treatment Saturday 20 February 2010
					
  
Patients with HIV who have a history of injecting drug use (IDU) appear
to get as much benefit from antiretroviral therapy as do patients with
HIV with no history of IDU.
  SOURCE:
Doctor's Guide




  GeoVax Labs, Inc. reports data on prototype adjuvant – suppplemented HIV vaccine tested in preclinical animal studies
  Prevention Saturday 20 February 2010
					
  
Results from study using non-human primates indicate 70% level of
protection from infection; Presentation made at Conference on
Retroviruses and Opportunistic Infections.
  SOURCE:
GeoVax Labs, Inc.




  U.S. company Virxsys says using AIDS to fight AIDS
  Prevention Saturday 20 February 2010
					
  
A company using genetically engineered versions of the AIDS virus says
its unusual approach is getting some results, both for treating and
perhaps as a vaccine against the virus.
  SOURCE:
REUTERS




  AIDS vaccine effects may wear off, researchers say
  Prevention Saturday 20 February 2010
					
  
An AIDS vaccine that appears to have worked at least partly in Thailand
may only temporarily protect patients, with the effects starting to
wane after a year or so, researchers reported on Thursday.
  SOURCE:
REUTERS




  UNAIDS welcomes South Africa’s new US$ 1.1 billion investment on AIDS for 2010
  World Policy Saturday 20 February 2010
					
  
South Africa makes the biggest domestic investment on AIDS by a developing country.
  SOURCE:
UNAIDS




  CROI: HIV ups risk of certain fractures
  Treatment Saturday 20 February 2010
					
  
People with HIV are at increased risk from fragility fractures in the hip or backbone, a researcher said. 
  SOURCE:
MedPage Today




  CROI: Nevirapine survives second test
  Treatment Saturday 20 February 2010
					
  
In women without prior exposure, nevirapine (Viramune) remains an effective anti-HIV drug, a researcher said here. 
  SOURCE:
MedPage Today




  CROI: Potency and staying power are goals of HIV pipeline research
  Treatment Saturday 20 February 2010
					
  
Research reported here suggests that the drug development pipeline for
HIV/AIDS therapies contains a mix of improved versions of standard HIV
drugs as well as agents aimed at new targets. 
  SOURCE:
MedPage Today




  Non-AIDS cancer risk decreases with higher CD4 cell counts
  Treatment Saturday 20 February 2010
					
  
Some good news regarding cancers: If antiretroviral therapy is able to
maintain higher CD4 cell counts, it may reduce the risk of various
non-AIDS-related cancers—notably those caused by other infectious
diseases, human papillomavirus (HPV), for example—in people living with
HIV. 
  SOURCE:
AIDSmeds.com




  Increased risk of chronic kidney disease linked to tenofovir and atazanavir
  Treatment Saturday 20 February 2010
					
  
Tenofovir was associated with a 16 percent increased risk of CKD per
year of exposure to the drug and atazanavir was associated with a 12
percent increased risk of CKD for every year the drug was used. 
  SOURCE:
AIDSmeds.com




  WHO-mandated CD4 monitoring for HIV shows poor sensitivity, specificity
  Treatment Saturday 20 February 2010
					
  
Reliance on CD4 monitoring instead of viral load monitoring can result
in the increased cost of second-line therapies for those misdiagnosed
as failures and increased risk for adverse events and development of
resistance in those mistakenly identified as having suppressed the
virus.
  SOURCE:
Medscape Today




  Vitamin D deficiency extremely common among HIV-positive patients in diverse regions 
  Treatment Saturday 20 February 2010
					
  
Vitamin D deficiency can result in bone density loss, cardiovascular
disease, diabetes and insulin resistance, kidney disease, and other
metabolic conditions commonly seen in patients with HIV. 
  SOURCE:
Aidsmap




  More evidence supports isoniazid for TB prevention in people with HIV 
  Tuberculosis & Malaria Saturday 20 February 2010
					
  
Two new studies add weight to a growing expert consensus that isoniazid
preventive therapy should be provided to people with HIV in order to
reduce the risk of developing active tuberculosis. 
  SOURCE:
Aidsmap




  Maraviroc showing tantalising promise as microbicide in preclinical studies 
  Prevention Saturday 20 February 2010
					
  
Two presentations at the 17th Conference on Retroviruses and
Opportunistic Infections (CROI) investigated the use of the CCR5
inhibitor maraviroc (licensed as Celsentri or Selzentry for HIV
treatment) as a possible vaginal and rectal microbicide. 
  SOURCE:
Aidsmap




  Smoking cessation lowers cardiovascular risk in D:A:D cohort 
  Treatment Saturday 20 February 2010
					
  
"The risk of cardiovascular disease events in HIV-positive patients
decrease with increasing time since stopping smoking. Smoking cessation
efforts should be a priority in the management of HIV-positive
patients." 
  SOURCE:
Aidsmap




  Treatment drive in British Columbia produces modest declines in diagnoses and viral loads 
  Prevention Saturday 20 February 2010
					
  
“Our results show an association between expanded HAART coverage,
decreased provincial plasma viral load, and decreased new HIV
diagnoses,” said Montaner. 
  SOURCE:
Aidsmap




  Immune restoration in DART study: late start means low CD4 count for years 
  Treatment Saturday 20 February 2010
					
  
While improvement was seen over several years, it remained
insignificant for those who began treatment with very low cell counts. 
  SOURCE:
Aidsmap


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20100220/77d47abb/attachment-0001.html>